Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6547965 | 0.98 | HTT (0.36) | HTTFURINSMN1; SMN2 | |
| SCHEMBL6547887 | 0.95 | HTT (0.39) | HTTFURINSMN1; SMN2L3MBTL1GAA | |
| SCHEMBL6548442 | 0.93 | HTT (0.39) | HTTFURINSMN1; SMN2L3MBTL1GAA | |
| SCHEMBL6548597 | 0.90 | HTT (0.39) | HTTFURINSMN1; SMN2L3MBTL1GAA | |
| SCHEMBL6549633 | 0.89 | HTT (0.38) | HTTFURINSMN1; SMN2L3MBTL1GAA | |
| SCHEMBL6548310 | 0.89 | HTT (0.38) | HTTFURINSMN1; SMN2L3MBTL1GAA | |
| SCHEMBL6548389 | 0.88 | HTT (0.37) | HTTFURINSMN1; SMN2L3MBTL1GAA | |
| SCHEMBL6548681 | 0.88 | HTT (0.39) | HTTFURINSMN1; SMN2L3MBTL1GAA | |
| SCHEMBL6548268 | 0.87 | HTT (0.39) | HTTFURINL3MBTL1GAAPPARG | |
| SCHEMBL6547864 | 0.87 | HTT (0.39) | HTTFURINSMN1; SMN2L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0975586-B1 | OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION | SUMITOMO CHEMICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-6448444-B2 | INSECTICIDES, MITICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-09-10 | — | — | US | disclosed |
| US-6437184-B1 | INSECTICIDES, ACARICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-08-20 | — | — | US | disclosed |
| US-20020019569-A1 | Oxime compounds, their use, and intermediates for their production | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019569-A1 | Oxime compounds, their use, and intermediates for their production | CBR3, CBR1, NOX3 | HTT 4052/4885FURIN 3892/4885SMN1; SMN2 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.